Compare LQDA & COLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | COLD |
|---|---|---|
| Founded | 2004 | 1903 |
| Country | United States | United States |
| Employees | N/A | 12690 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.4B |
| IPO Year | 2020 | 2009 |
| Metric | LQDA | COLD |
|---|---|---|
| Price | $35.18 | $11.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $41.00 | $15.32 |
| AVG Volume (30 Days) | 1.2M | ★ 3.7M |
| Earning Date | 03-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 8.41% |
| EPS Growth | ★ 51.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $158,320,000.00 | ★ $2,601,846,000.00 |
| Revenue This Year | $265.61 | N/A |
| Revenue Next Year | $62.82 | $2.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1031.18 | N/A |
| 52 Week Low | $11.26 | $10.10 |
| 52 Week High | $46.67 | $21.59 |
| Indicator | LQDA | COLD |
|---|---|---|
| Relative Strength Index (RSI) | 45.92 | 42.19 |
| Support Level | $31.75 | $11.06 |
| Resistance Level | $36.07 | $13.44 |
| Average True Range (ATR) | 1.80 | 0.45 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 16.87 | 42.21 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Americold Realty Trust Inc is the world's second-largest owner and operator of temperature-controlled warehouses behind privately held Lineage Logistics. The Atlanta, Georgia-based firm owns and operates approximately 231 temperature-controlled warehouses, spanning 1.4 billion cubic feet. In 2022, the firm derived more than 80% of its revenue from the United States but also has sizable operations in Europe, Canada, Australia, and New Zealand. Americold supplements its core business by providing supply management and transportation services to its various customers. It operates as a real estate investment trust.